06990.HK
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 489.40
−1.49%Aug 17, 2026, 11:11 UTC
Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.
Jul 30, 2026, 09:07 UTC
Kelun-Biotech's new drug application for sac-TMT (TROP2 ADC) for a new indication in first-line treatment of recurrent or metastatic triple-negative breast cancer has been accepted for review by China's NMPA.
Jul 28, 2026, 01:36 UTC
China's National Medical Products Administration approved Hengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical to conduct Phase II/III clinical trials for HRS-1780 tablets for hypertension.
Source:Jul 27, 2026, 11:07 UTC
Kelong Pharmaceutical's subsidiary Kelun-Biotech's SKB565 new drug clinical trial application was approved by China's National Medical Products Administration for the treatment of advanced solid tumors.
Source:Jul 21, 2026, 19:36 UTC
Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.
Jul 15, 2026, 10:02 UTC
HBM7575/SKB575, a bispecific antibody for asthma, received IND approval from China's NMPA.
Source: